Contact
18 Jun 20
News
18 Jun 20

Biocomposites announces STIMULAN® products added to NHS Supply Chain

STIMULAN is the first calcium matrix to receive European approval as an antibiotic carrier for use in bone and soft tissue

Keele, UK,  18 June 2020 – Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, today announced that its STIMULAN® and genex® products have been added to the NHS Supply Chain’s Total Orthopaedic Solutions 2 (“TOS2”) framework agreement.  NHS Supply Chain manages the sourcing, delivery and supply of healthcare products and services for NHS trusts and healthcare organisations across England and Wales and TOS2 provides a single source for NHS Trusts to purchase orthopaedic products.

STIMULAN recently gained a new European CE mark approval for mixing with antibiotics: vancomycin, gentamicin and tobramycin. It is the only calcium matrix approved for use in bone and soft tissue and targets high concentrations of antibiotic at the point of infection at levels unachievable systemically – which lowers rates of reinfection, saves hospital costs and improves patient outcomes. STIMULAN is the only product of its type available through the TOS2 agreement.

The NHS Supply Chain was designed to help the NHS deliver clinically assured, quality products at the best value. The TOS2 agreement provides competitive national pricing and builds on TOS1 which secured over 50% of all spend in scope across the English NHS, with the aim of rising to over 90% with TOS2.

The NHS adoption of STIMULAN builds on the product’s commendable traction worldwide and it is the option of choice for influential surgeons managing infection, offering them the flexibility to use their chosen antibiotics at patient-specific concentration levels in both bone and soft tissue.

Michael Harris, Chief Executive Officer of Biocomposites, said: “STIMULAN is already used in over 50,000 cases every year in thousands of hospitals around the world. As the only calcium sulfate antibiotic carrier approved for use in bone and soft tissue, our addition to TOS2 makes it even easier for hospitals and surgeons to access this breakthrough solution as part of their infection management strategy.”

Contact for Media enquiries

Optimum Strategic Communications
Mary Clark, Stephen Adams, Katie Flint
Tel: +44 (0)20 3882 9621
biocomposites@optimumcomms.com

About Biocomposites

Biocomposites is an international medical devices company that engineers, manufactures, and markets world leading products for use in infection management in bone and soft tissue. Based in Keele, UK, it has global operations across Europe, USA, Argentina, Canada, China, and India. Biocomposites is a world leader in the development of innovative calcium compounds and bone cements for surgical use. Its products regenerate bone and target infection risks across a variety of specialties, including musculoskeletal infection, orthopaedics, trauma, spine, foot and ankle, podiatry, and sports injuries. Biocomposites products are now used in over one million procedures per annum and sold in more than 100 countries around the world. Please visit biocomposites.com to learn more.

Other news

Listed below is a list of the 4 most recent news updates made by Biocomposties


Visit our News & Events page

Library

Interested in other types of our content? See a list of some of our most recent below.

Explore Library